financetom
Business
financetom
/
Business
/
Knowles Q4 Non-GAAP Earnings, Revenue Rise -- Shares Fall After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Knowles Q4 Non-GAAP Earnings, Revenue Rise -- Shares Fall After Hours
Feb 13, 2025 2:27 PM

05:07 PM EST, 02/13/2025 (MT Newswires) -- Knowles ( KN ) reported Q4 non-GAAP earnings late Thursday of $0.27 per diluted share, up from $0.22 per share a year earlier.

Four analysts polled by FactSet expected $0.28.

Revenue for the quarter ended Dec. 31 was $142.5 million, up from $139.2 million a year earlier.

Four analysts surveyed by FactSet expected $146 million.

For Q1, the company expects non-GAAP diluted earnings from continuing operations of $0.16 to $0.20 and revenue of $124 to $134 million.

Four analysts polled by FactSet expect non-GAAP EPS of $0.22 and sales of $135.9 million.

Knowles ( KN ) said its board approved a $150 million increase to its existing stock repurchase program, originally adopted in February 2020.

As of Feb. 13, the total available funds for repurchases under the program, including this new authorization, amount to about $194 million.

The shares of Knowles ( KN ) were down over 10% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
S&P Global Names Eric Aboaf CFO
S&P Global Names Eric Aboaf CFO
Oct 17, 2024
08:57 AM EDT, 10/15/2024 (MT Newswires) -- S&P Global ( SPGI ) said Tuesday that it has named Eric Aboaf as its chief financial officer, effective February. Aboaf was most recently the CFO of State Street (STT). Price: 528.96, Change: +1.44, Percent Change: +0.27 ...
Knight Therapeutics Anti-Cancer Treatment Gains Approval in Mexico
Knight Therapeutics Anti-Cancer Treatment Gains Approval in Mexico
Oct 17, 2024
08:57 AM EDT, 10/15/2024 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Tuesday said its Mexican affiliate has obtained regulatory approval for Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that aren't eligible for autologous stem cell transplantation. The treatment is expected to launch in the first half of next...
Platinum Equity's Ingram Micro seeks up to $5.4 bln valuation in US IPO
Platinum Equity's Ingram Micro seeks up to $5.4 bln valuation in US IPO
Oct 17, 2024
* Ingram, PE firm seek to raise as much as $428 mln * Platinum Equity will remain controlling shareholder post-IPO * Ingram set to go public again, 28 years after initial NYSE debut (Adds background on company and IPO details in paragraphs 4-12) Oct 15 (Reuters) - Ingram Micro is targeting a valuation of up to $5.42 billion in its...
Johnson & Johnson Reports Positive Phase 2/3 Study Results for Nipocalimab in Myasthenia Gravis Adolescents
Johnson & Johnson Reports Positive Phase 2/3 Study Results for Nipocalimab in Myasthenia Gravis Adolescents
Oct 17, 2024
08:59 AM EDT, 10/15/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday its phase 2/3 Vibrance-MG study of nipocalimab in adolescents with generalized myasthenia gravis met its primary endpoint by achieving sustained disease control. Treatment with nipocalimab plus standard of care reduced immunoglobulin G levels by 69% over 24 weeks, the company said. The combination treatment also...
Copyright 2023-2025 - www.financetom.com All Rights Reserved